Objective The aim of this study was to identify baseline peripheral blood biomarkers associated with clinical outcome in patients with NSCLC treated with nivolumab. Methods Univariable and multivariable analyses were performed retrospectively for 134 patients with advanced or recurrent NSCLC treated with nivolumab to evaluate the relationship between survival and peripheral blood parameters measured before treatment initiation, including absolute neutrophil count (ANC), absolute lymphocyte count (ALC), absolute monocyte count, and absolute eosinophil count (AEC), as well as serum C‐reactive protein and lactate dehydrogenase levels. Progression‐free survival, overall survival, and response rate were determined. Results Among the variables selected by univariable analysis, a low ANC, high ALC, and high AEC were significantly and independently associated with both better progression‐free survival (p = 0.001, p = 0.04, and p = 0.02, respectively) and better overall survival (p = 0.03, p = 0.03, and p = 0.003, respectively) in multivariable analysis. Categorization of patients according to the number of favorable factors revealed that those with only one factor had a significantly worse outcome than those with two or three factors. A similar trend was apparent for patients with a programmed death 1 ligand tumor proportion score less than 50%, whereas all patients with a score of 50% or higher had at least two favorable factors. Conclusions A baseline signature of a low ANC, high ALC, and high AEC was associated with a better outcome of nivolumab treatment, with the number of favorable factors identifying subgroups of patients differing in survival and response rate.

中文翻译：

---

与接受纳武单抗治疗的非小细胞肺癌患者临床结果相关的外周血生物标志物

目的 本研究的目的是确定与接受纳武单抗治疗的 NSCLC 患者的临床结果相关的基线外周血生物标志物。方法 回顾性对 134 例接受纳武单抗治疗的晚期或复发性 NSCLC 患者进行单变量和多变量分析，以评估生存期与治疗开始前测量的外周血参数之间的关系，包括绝对中性粒细胞计数（ANC）、绝对淋巴细胞计数（ALC）、绝对值。单核细胞计数和绝对嗜酸性粒细胞计数 (AEC)，以及血清 C 反应蛋白和乳酸脱氢酶水平。确定了无进展生存期、总生存期和反应率。结果 在通过单变量分析选择的变量中，低 ANC、高 ALC、和高 AEC 与更好的无进展生存期（分别为 p = 0.001、p = 0.04 和 p = 0.02）和更好的总生存期（分别为 p = 0.03、p = 0.03 和 p = 0.003）显着且独立相关) 在多变量分析中。根据有利因素的数量对患者进行分类显示，只有一个因素的患者的结果明显比有两个或三个因素的患者更差。对于程序性死亡 1 配体肿瘤比例评分低于 50% 的患者，类似的趋势很明显，而所有评分为 50% 或更高的患者至少有两个有利因素。结论 低 ANC、高 ALC 和高 AEC 的基线特征与 nivolumab 治疗的更好结果相关，